Johnson & Johnson



Drug & Biotechnology



1 Johnson And Johnson Plaza
New Brunswick
NJ 08933
United States

Tel: +1 (732) 524-2455
Fax: +1 (732) 214-0332
Email: N/A



  • FTSE4Good Index
  • CDP Water Security A list
  • CDP Climate Change A list
  • CDP Forest  Program A-score
  • 90% in DisabiltyIN’s 2019 Disability Equality Index for the second consecutive year
  • Top 100 Companies in Equileap’s 2019 Gender Equality Global Report and Ranking
  • Member of the Billion Dollar Roundtable for supplier diversity for the ninth consecutive year
  • Human Rights Campaign Foundation’s list as the Best Place to Work for LGBTQ Equality for the 15th consecutive year, scoring 100% on the 2020 Corporate Equality Index (CEI)
  • American Heart Association at Gold Level for workplace health programs and culture of health best practices
  • Billion Dollar Roundtable, a group of companies that advanced best practices for supplier diversity, and that spend at least $1 billion (Tier 1) annually with certified minority-, women-, veteran-, LGBT- and disability-owned businesses.
  • #11 in the 2019 Workforce 100 – the world’s top companies for Human Resources Management
  • #87 World’s Best Employers 2020
  • #45 Just Companies 2021
  • #30 Best Employers for New Grad 2020
  • America’s Best Employers By State 2020
  • #121 Best Employers for Women 2020
  • #34 Global 2000 2020
  • #81 Canada’s Best Employers 2020
  • #28 Best Employers for Diversity 2020
  • #63 Top Regarded Companies 2019 
  • #88 America’s Best Employers 2019 
  • #45 America’s Largest Public Companies 2018 
  • #50 World’s Most Powerful Brands 2012




Philip Dahlin


  • #1 on Gartner’s 2019 Healthcare Supply Chain Top 25 list
  • #3 in the 2020 Antimicrobial Resistance Benchmark
  • EPA SmartWay Excellence Award for the sixth year. This award recognizes companies that are leaders in increasing energy efficiency while decreasing greenhouse gas emissions.
  • CSR Health Impact’s Swasth Bharat award in recognition of Janssen India’s transformative work to address the growing challenge of multidrug-resistant tuberculosis 
  • Named to Fortune’s list of the World’s Most Admired Companies for the 17th year, ranking in the top 20



Report created by Katerina Vargova

Johnson & Johnson

SECTIONS :  Sustainability    Evaluation  •  Progress  •  Watch  •  Overview

Company Activity

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886. Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

The Consumer segment includes a range of products used in the baby care, oral care, skincare, over-the-counter pharmaceutical, women’s health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases.

The Medical Devices segment includes a range of products used in the orthopaedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Company Sustainability Activity

As the world’s largest healthcare company, Johnson & Johnson has a unique ability to apply its expertise and partnering power to solve some of the most difficult global health challenges. J&J is advancing a world where healthy people thrive in healthy communities on a healthy planet, and having a healthy company helps us get there. 

J&J focuses its sustainability efforts where J&J can achieve the greatest impact. J&J’s Health for Humanity 2020 Goals are aligned with J&J’s purpose and reflect the areas where its stakeholders expect them to lead.

The Sustainable Development Goals (SDGs) are a global framework for progress toward a more sustainable future. In trying to determine the ways in which J&J can contribute to the global community to create a healthier, more equitable world, J&J developed a clear, pragmatic process for building a commitment to accelerate the SDGs that reflects its unique constellation of strengths.


  • $11.4 billion invested in R&D
  • 105,000 patients provided access to HIV treatment
  • 106,000 patients provided access to MDR-TB treatment
  • $37 million donated for disaster relief to support communities
  • 75,000 health workers educated in 54 countries
  • 30% of electricity is produced or procured from renewable energy sources
  • 32% reduction in CO2 emissions since 2010
  • 46% of management roles held by women


  • Collaborate on Phase 3 trials and make regulatory submissions for rilpivirine long-acting (LA), the first all-injectable depot regimen for HIV
  • Produce and donate 1 billion doses of VERMOX (mebendazole) to treat >100 million children per year at risk for intestinal worms
  • Deliver HIV/AIDS therapy access to cumulative 130,000 adults and 5,000 children
  • Deliver access to MDR-TB therapy to a cumulative 200,000 patients, potentially curing 157,000 people with MDR-TB of the disease.
  • Together with partners, train 30,000 skilled birth attendants to assist 6 million births
  • Support the delivery of 6 million eye care screenings to underserved children and corrective treatments (spectacles) as needed to 100,000 underserved children.
  • Activate signature partnerships/initiatives for five of their largest Consumer Health brands to promote the health and wellbeing of people in need around the world.
  • Drive policy thought leadership and strategic engagements to expand healthcare access and coverage in at least three emerging markets (including Brazil, China and India), and lead three to five pilots to demonstrate the results of these efforts.
  • New and existing products representing 20% of J&J revenue achieve EARTHWARDS recognition for sustainable innovation improvements
  • Increase the recyclability of Consumer Health product packaging to 90+% (on a weight basis) via design and partnerships in five key markets where mature recycling infrastructure exists (Canada, France, Germany, UK and U.S). In three other markets where recycling infrastructure is less mature to engage in partnerships to advance material recovery and recycling efforts.
  • Reduce absolute carbon emissions 20% by 2020, and 80% by 2050
  • Produce/procure 35% of electricity from renewable sources by 2020; aspire to power all facilities with renewable energy by 2050
  • Conduct a comprehensive water risk assessment at 100% of manufacturing/R&D locations and implement resource protection plans at the high-risk sites


  • One submission to the U.S. Food and Drug Administration (FDA) by ViiV Healthcare for ViiV’s cabotegravir LA together with Janssen’s rilpivirine LA. Two parallel submissions to the European Medicines Agency – one for rilpivirine LA by Janssen and one for cabotegravir LA by ViiV Healthcare.
  • 0.8 billion doses of VERMOX donated in 42 countries with 415 million children having been targeted for treatment
  • 104,000 adult patients (130,000 targets) and over 700 pediatric patients (5,000 targets) received access to HIV/AIDS therapy with the branded and generic versions of PREZISTA (darunavir), INTELENCE (etravirine) and EDURANT (rilpivirine)
  • 182,000 patients received access to MDR-TB therapy with SIRTURO (bedaquiline). For 37,000 patients provided access in 2016 and 2017, an estimated 32,000 patients have been potentially cured based on the 87.8% cure rate.
  • Together with partners, trained 74,000 skilled birth attendants, who assisted in 6 million births
  • In partnership with Lions Club International, supported the delivery of 12 million eye care screenings and corrective treatments (spectacles) to 120,000 underserved children.
  • BAND-AID® Brand Adhesive Bandages activated the partnership with (RED) to help fund a diverse range of lifesaving HIV/AIDS programs across eight countries in sub-Saharan Africa. In prior years J&J activated partnerships with JOHNSON’S, LISTERINE, and STAYFREE. 
  • More than 800 engagements conducted with government officials and other partners in Brazil, China, Malaysia, Mexico, Russia and Rwanda in 2019. Existing pilot projects to expand healthcare access and coverage in Brazil, China, Colombia, Indonesia, Mexico, Philippines, Russia and Rwanda are ongoing. Two new pilots launched: a private health insurance project in Malaysia to expand access to innovative medicines and premium surgical products; and a project in China to improve the case finding and diagnosis of TB, including drug-resistant TB.
  • New and existing products representing 22% of J&J revenue achieved EARTHWARDS recognition.
  • Continued partnerships with two co-ops in Brazil and one in India to advance material recovery and recycling efforts. Concluded the partnership in Vietnam focused on ocean plastics through the Consumer Goods Forum and Trash Free Seas Alliance.
  • CO2 emissions decreased by 32% globally since 2010 (Scope 1 and Scope 2)
  • 30% of electricity is produced or procured from renewable energy sources
  • J&J completed the comprehensive water risk assessment at 100% of manufacturing/R&D locations in 2019. By the end of 2019, 100% of all high-risk sites identified developed mitigation plans and budgeted for their implementation in 2020; 35% of these have already completed their mitigation plans.


  • ISO 45001/OHSAS 18001 – 24% of J&J’s manufacturing and R&D sites were certified
  • ISO 14001 – 97% of manufacturing and R&D sites certified 
  • LEED – 13% of all built space certified (goal is LEED certification for all new J&J buildings and renovations of $5 million or more)
  • ERM CVS –  to provide limited assurance on cumulative progress over 2016 – 2019 against the Health for Humanity 2020 Goals reported in the J&J 2019 Health for Humanity Report

United Nations Sustainable Development Goals

United Nations SDGs Compliance


  • J&J aspiration: A world where the current and future health care workforce has the necessary competencies to deliver high-quality health care.
  • J&J 5-year target: 650,000 health workers will have received training to better deliver quality health care.


  • J&J aspiration: A world where every woman and child survives and has the opportunity for a healthy future.
  • J&J 5-year target: 60 million women and children will have received support and tools to enable a healthy future.

SDG 17

  • J&J 5-year target: 60 million citizens living across 30 cities will have benefited from climate and air quality actions that have the potential to positively impact public health.
  • A world where innovations and holistic health solutions prevent, control and eliminate global disease challenges and epidemics. 175 million individuals will have benefited from J&J solutions that prevent, control and eliminate global diseases.
  • A world where safe, essential and timely surgical care can be accessed by all to save lives, prevent disability, promote economic growth, and reduce social marginalization. 5-year target: 50 million people will have had access to safe, essential, and timely surgical care.


Johnson & Johnson is an internationally recognized brand, listed in indices like FTSE4Good Index and CDP. J&J has received many awards and ranks at the top of the Forbes rankings. J&J has a few ISO certificates and LEED-certified buildings. 

J&J comply with 3 of the UN Sustainable Development Goals, although many sustainable J&J activities address more SDGs than 3 mentioned in its 2030 promise.

For its sustainable activities, and clear reporting is Johnson & Johnson rated B.

Analyst Outlook: Negative

Although J&J covers many sustainable areas, its progress in reducing CO2 emissions is insufficient (CO2 emissions reduced by 32% since 2010) and only 30% of electricity comes from renewable sources.

In recent years, J&J has faced cases in the United States and Australia that have challenged J&J’s ethics and practices toward its consumers.

In addition, Johnson & Johnson and its subsidiaries helped fuel Oklahoma’s opioid crisis.


Key Points

  • CO2 emissions decreased by 32% globally since 2010 (Scope 1 and Scope 2)
  • 30% of electricity is produced or procured from renewable energy sources
  • 2,247 TJ annual energy saving
  • J&J’s Healthy Lives Mission includes conversion to 100% recyclable, reusable or compostable plastic, and recycled paper and pulp-based packaging by 2025.
  • In 2019, J&J was again named to the CDP supplier engagement leader board. J&J was the first healthcare company to achieve this position in 2018 and the first healthcare company to do so for three years in a row.
  • Australia’s Federal Court found that J&J subsidiary Ethicon failed to warn patients and surgeons about the “risks” posed by the vaginal mesh implants. More than 1,350 Australian women have won a long-running class-action lawsuit against J&J over vaginal mesh implants.
  • In the U.S. J&J has recalled 33,000 bottles of baby powder in the US after health regulators found trace amounts of asbestos in a bottle purchased online. Some juries have awarded millions in damages, while others have denied the claims.
  • Their longstanding commitment to healthcare makes them a highly valuable company that has and has benefited society in a significant way
Share this Post